PR Newswire (press release)Benson Hill Biosystems Receives Patent for Novel CRISPR TechnologyPR Newswire (press release)"Consistent with their commitment to empowerment and community, the Benson Hill team has proactively disseminated their CRISPR … Continue reading
Endpoints News |
AbbVie, Voyager Launch Up-to-$1.1B+ Gene–Therapy Collaboration to Treat Alzheimer’s, Neurodegenerative Diseases
Genetic Engineering & Biotechnology News AbbVie will partner with Voyager Therapeutics to develop and commercialize gene therapies for Alzheimer’s disease and other neurodegenerative diseases, through a collaboration that could generate more than $1.1 billion-plus for Voyager, the companies … With $69M Deal, AbbVie Turns to Voyager for an Alzheimer’s Gene TherapyXconomy AbbVie steers past the wreckage, reserves $224M to kick off once-and-done gene therapy with Voyager to fight …Endpoints News Voyager Therapeutics (VYGR), AbbVie (ABBV) Enter Pact to Develop Potential New Treatments for Alzheimer’s …StreetInsider.com BioPharma Dive –FierceBiotech –The Pharma Letter all 9 news articles » |
Boston Business Journal |
AbbVie, Voyager Launch Up-to-$1.1B+ Gene–Therapy Collaboration to Treat Alzheimer’s, Neurodegenerative Diseases
Genetic Engineering & Biotechnology News AbbVie will partner with Voyager Therapeutics to develop and commercialize gene therapies for Alzheimer’s disease and other neurodegenerative diseases, through a collaboration that could generate more than $1.1 billion-plus for Voyager, the companies … Cambridge’s Voyager, AbbVie to pursue Alzheimer’s gene therapy under $69M dealBoston Business Journal With $69M Deal, AbbVie Turns to Voyager for an Alzheimer’s Gene TherapyXconomy AbbVie steers past the wreckage, reserves $224M to kick off once-and-done gene therapy with Voyager to fight …Endpoints News GlobeNewswire (press release) –BioPharma Dive –FierceBiotech all 9 news articles » |
|
CAR–T growing up with big pharma’s big bet
BioPharma Dive In the span of just five months, Gilead Sciences Inc. and Celgene Corp. — both large-cap biotechs with long-term growth worries — each made major bets on the potential of cancer cell therapies. With two of the three largest biotech deals in the last … |